According to the Zhitong Finance App, Libang Instruments (300206.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 1,024 billion yuan, an increase of 12.01% over the previous year. Achieved net profit of 202 million yuan attributable to shareholders of listed companies, an increase of 30.68% over the previous year. Achieved net profit of 191 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 32.03% over the previous year.
During the reporting period, the company's international business achieved revenue of 66,0417 million yuan, an increase of 18.50% over the previous year, accounting for about 64.53% of the company's overall revenue, an increase of about 3.54% over the same period last year, further highlighting the results of the implementation of the internationalization strategy. Relying on high-quality products, professional services and continuous deepening overseas localization, the company continues to expand its overseas market footprint. The five hardware product lines have all achieved good growth in overseas markets. The international business has become the core engine for the company's performance growth, providing strong support for the company's overall business scale expansion and profitability improvement.
During the reporting period, the company's domestic business achieved revenue of 36,0776,900 yuan, an increase of 1.85% over the previous year. Although the pace of release of procurement demand from domestic medical institutions is still affected by macroeconomic environment and industry policy adjustments, the company stabilized the basic domestic business market through various countermeasures such as optimizing internal management, adjusting product structure, and improving service quality. Domestic revenue increased 1.85% year on year. Compared with the 12.56% decline in the same period in 2025, it successfully achieved a steady recovery.